Treating benign prostatic hyperplasia
US11602516B1 · kind B1 · utility
0Cited by
19References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 22, 2022 |
| Grant date | Mar 14, 2023 |
| Priority date | — |
| Expiry date | Apr 22, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/416
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.